I have been following Adamas Pharmaceuticals (ADMS) ever since they were able to receive FDA approval for their flagship product GOCOVRI for PD dyskinesia and OFF. Since then, I have started writing for Seeking Alpha and decided to write about my Adamas journey. Most of my writing has been focused around quarterly earnings reports and how the market has reacted to those reports. This investment and my ADMS coverage have taught me a great deal about the interactions between the street, the company, the providers, the patients, and the investors. At one point,